Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Additional Broker Option - Extension

28 Apr 2023 07:00

RNS Number : 7859X
Belluscura PLC
28 April 2023
Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK version of the Market Abuse Regulation (EU) No.596/2014, which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

Β 

Belluscura plc

Β 

("Belluscura", the "Company" or the "Group")

Β 

Additional Broker Option - Extension

Β 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, provides an update further to its announcement on 10 February 2023 (headed "Result of Broker Option; Additional Broker Option").

Β 

Additional Broker Option

Β 

As announced on 10 February 2023, in addition to theΒ $5.8 million (Β£4.7 million), before expenses raised in Loan Notes in the Placing and Broker Option, Dowgate had identified significant further potential demand for the Loan Notes from placees.

Β 

As a result, the Company agreed to issue an additional broker option ("Additional Broker Option") to enable Dowgate to arrange the placing of further loan notes to raise up to an additional approximately $4.2 millionΒ (Β£3.4 million)Β (the "Additional Broker Option Loan Notes"). This Additional Broker Option was originally scheduled to expire on 28 April 2023. Under the Placing Agreement the Long Stop Date for issuance of the Loan Notes is 12 May 2023, subject to agreement with Dowgate and SPARK.

Β 

Interest for significant further demand in the Loan Notes from prospective placees remains, however, Dowgate has advised the Company that these prospective placees require more time, and consequently the Company, Dowgate and SPARK have agreed to allow Dowgate to exercise the Additional Broker Option up to 16 June 2023 and any Additional Broker Option Loan Notes will be issued by the Company on 23 June 2023 with a revised Long Stop Date of 30 June 2023. Accordingly, the Placing Agreement and the Instrument were further amended and restated on 27 April 2023 to extend the deadlines related to the exercise of the Additional Broker Option and the issue of Additional Broker Option Loan Notes thereunder.

Β 

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released on 27 January 2023 and/or 10 February 2023 unless the context requires otherwise.

For further information please contact:

Β 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman

Robert Rauker, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

Β 

SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin

Β 

Dowgate Capital Limited

Broker and Bookrunner

Tel: +44 (0)20 3903 7715

James Serjeant / Russell Cook

Β 

MHP

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

Katie Hunt/Pete Lambie/ Matthew Taylor

Β email: Belluscura@mhpgroup.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCIRMMTMTITTJJ
Date   Source Headline
12th Oct 202312:42 pmBUSForm 8.3 - Belluscura plc
12th Oct 20239:55 amRNSForm 8.3 - BELLUSCURA PLC
11th Oct 20234:20 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20235:10 pmRNSForm 8.3 - TMT ACQUISITION PLC
10th Oct 20235:09 pmRNSForm 8.3 - [BELLUSCURA PLC]
10th Oct 20234:40 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20234:21 pmRNSForm 8.3 - BELLUSCURA PLC
10th Oct 20234:19 pmRNSForm 8.3 - TMT Acquisition PLC
10th Oct 20233:54 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:52 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:47 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:42 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:28 pmGNWForm 8.3 - Belluscura PLC
9th Oct 20236:11 pmRNSForm 8.3 - Belluscura Plc
9th Oct 20232:32 pmRNSForm 8.3 - Belluscura PLC
9th Oct 20231:39 pmRNSRule 2.9 Announcement
9th Oct 20238:10 amRNSRule 2.9 Announcement
6th Oct 202312:48 pmRNSConditional Allotment and Issue of Placing
5th Oct 20234:49 pmRNSForm 8.3 - Belluscura PLC
3rd Oct 20236:28 pmRNSReplacement - Placing of Unsecured CLNs
3rd Oct 20231:53 pmRNSDirectorate Change
3rd Oct 20231:38 pmRNSPlacing of Unsecured Convertible Loan Notes
3rd Oct 20231:30 pmRNSStatement regarding possible offer
3rd Oct 20231:30 pmRNSStatement re Possible Offer
26th Sep 20237:00 amRNSBelluscura Receives Approval in Hong Kong
14th Sep 20234:26 pmRNSResult of AGM
13th Sep 20237:00 amRNSHalf-year Report
30th Aug 20237:00 amRNSBelluscura Enters Exclusive License Agreement
16th Aug 20237:00 amRNSOrders for over 6,500 DISCOV-R™ received
1st Aug 20237:00 amRNSBelluscura Signs Distribution Agreement
12th Jul 20237:00 amRNSNotice of AGM and Annual Report 2022
29th Jun 20237:00 amRNSBelluscura Commences Premarket Launch of DISCOV-R™
29th Jun 20237:00 amRNSFinal Results for the year ended 31 December 2022
15th Jun 20237:00 amRNSShare allotment; Director/PDMR Shareholding; Appt.
14th Jun 202312:28 pmRNSResult of General Meeting
1st Jun 20237:00 amRNSResult of Retail Offer
26th May 20237:00 amRNSProposed Board Appointment
25th May 202311:15 amRNSRetail Offer to raise up to £0.5m
25th May 202311:00 amRNSProposed Placing and Subscriptions to raise £3.0m
28th Apr 20237:00 amRNSAdditional Broker Option - Extension
20th Apr 20238:19 amRNSExercise of Warrants and Total Voting Rights
3rd Apr 20237:00 amRNSBelluscura begins manufacturing in China
30th Mar 20237:00 amRNSChange of Auditor
24th Feb 20237:00 amRNSBelluscura POC now marketed through GoodRx®
16th Feb 202311:59 amRNSResult of General Meeting
10th Feb 20237:00 amRNSResult of Broker Option
31st Jan 20233:41 pmRNSPosting of Circular
27th Jan 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.